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Abstract
Mutational processes and signatures that drive early tumorigenesis are centrally important
for early cancer prevention. Yet, to date, biomarkers and risk factors for polyps (adenomas)
that inordinately and rapidly develop into colon cancer remain poorly defined. Here, we
describe surprisingly high mutational profiles through whole-genome sequence (WGS)
analysis in 2 of 4 pairs of benign colorectal adenoma tissue samples. Unsupervised hierar-
chical clustered transcriptomic analysis of a further 7 pairs of adenomas reveals distinct
mutational signatures regardless of adenoma size. Transitional single nucleotide substitu-
tions of C:G>T:A predominate in the adenoma mutational spectrum. Strikingly, we observe
mutations in the TGF-β pathway and CEA-associated genes in 4 out of 11 adenomas, over-
lapping with the Wnt pathway. Immunohistochemical labeling reveals a nearly 5-fold
increase in CEA levels in 23% of adenoma samples with a concomitant loss of TGF-β sig-
naling. We also define a functional role by which the CEA B3 domain interacts with
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TGFBR1, potentially inactivating the tumor suppressor function of TGF-β signaling. Our
study uncovers diverse mutational processes underlying the transition from early adenoma
to cancer. This has broad implications for biomarker-driven targeting of CEA/TGF-β in high-
risk adenomas and may lead to early detection of aggressive adenoma to CRC
progression.
Introduction
Advanced colorectal cancer (CRC) remains the third most common cancer in both men and
women, with approximately 1.3 million new CRC cases diagnosed in the world every year [1].
Late-stage disease continues to have a dismal survival rate, with over 45% of patients dying of
recurrence despite adjuvant therapy [2]. Early detection, prevention, and screening have been
central to reducing mortality rates [3–5]. However, these processes are limited by variations
among subjects, variability in the sensitivity of the screening procedure, and lack of reliable
methods of identification of early high-risk patients. High risk adenomas are conventionally
defined clinically as those that are larger than 1 cm. These adenomas are considered to give rise
to overt carcinomas and are an important criterion in colonoscopy and screening studies [3, 4,
6, 7]. Moreover, while sequence analyses demonstrating increased numbers of somatic muta-
tions correlate with increased cancer risk have been well documented in many cancers, these
have yet to be clearly described for colon adenomas [8–11]. In addition, the driving pathways
in CRC have been defined to a large (though not complete) extent- the APC-Wnt and TGF-β
pathways have been established as modulators of GI stem cells and drivers of CRC. Thus muta-
tions in members of these pathways would carry further significance [12]. It is becoming
increasingly clear both that CRC can be missed because it may occur rapidly and that other
risk factors and mutational processes may be involved [6].
Several critical drivers and pathways important for the initiation and progression of CRC
have been identified and investigated extensively [12–15]. These include the WNT, TGF-β,
RAS-MAPK, PI3K, P53, and DNAmismatch-repair pathways. Still, limited insight exists into
the determinants of early colorectal neoplasia, including the full spectrum of molecular drivers
involved in colorectal neoplastic initiation and pre-invasive progression. In addition, muta-
tional processes and signatures remain poorly characterized in adenomas which could lead to
CRC. We hypothesized that defining such mutational signatures could identify rapid progres-
sors to overt CRC as well as new targets for CRC prevention.
In the present study, we conducted whole-genome sequencing on 4 pairs of adenoma sam-
ples and whole-transcriptome RNA sequencing on 7 matched colon adenoma samples and
normal mucosa. Using unsupervised hierarchical clustering, we observed distinct mutational
signatures in the TGF-β pathway and CEA-associated genes, overlapping with the Wnt path-
way. Critically, we find a marked increase of CEA levels (nearly 5-fold) in 23% of adenoma
samples with commensurate loss of TGF-β signaling and provide mechanistic insight of CEA-
mediated TGF-β signaling. Our findings may lead to early detection of aggressive adenoma-
CRC progression. Furthermore, these findings have broad implications for cancer prevention,
particularly in view of the availability of a CEA vaccine that may be amenable to a high-risk
population.
Results
Genome-wide analysis enables predictive modeling of genetic pathways which drive many can-
cers, genetic diseases, and human syndromes [16, 17]. To gain a comprehensive understanding
of the mutational landscape of genetic alternations taking place in adenomas, whole-genome
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sequencing (WGS) analysis for 4 adenoma samples was carried out, with a further whole-tran-
scriptome sequencing (WTS) of 7 pairs of matched colon adenoma samples and normal
mucosa (S1 Fig and S1 Table). Through the analyses of WGS and WTS data, we detected 7358
non-synonymous somatic mutations in 4610 genes. The WGS shows 1709 average mutations
after normalization with an average mutation frequency of 0.55 mutations per 106 bases. Aber-
rant mutational profiles are detected with distinct mutational signatures among the WGS sam-
ples: two samples with high mutation rates (>1.0 mutations/106 bases): MDA50ad-TA and
MDA51ad-SSA (Fig 1A); two with low mutation rates: MDA49ad-TA and MDA80ad-SSA (Fig
1A). Compared with colon carcinomas in The Cancer Genome Atlas (TCGA) cohort, the two
samples with the highest mutations we screened have similar rates to that of non-hypermutated
samples in TCGA colon carcinomas [12]. Even though the mutation rates detected by RNA
sequencing may be affected by RNA editing, gene transcripts and tumor heterogeneity [18],
the WTS indicate 74 average mutations after normalization with an average mutation fre-
quency of 1.02 mutations per 106 bases (S1 Table). The WTS samples also indicate aberrant
mutational profiles: MDA27ad-TA and MDA34ad-TVA with high mutation rates; MDA1ad-
TA, MDA2ad-TVA, MDA3ad-SSA and MDA33ad-TA with intermediate mutation rates;
MDA31ad-TA with low mutation rates (S2A Fig). Furthermore, we find that transitional single
nucleotide substitutions of C:G> T:A predominate in both adenoma mutational spectrums
and TCGA colon carcinomas (Fig 1B and S2B Fig).
CRC TCGA studies have validated that frequent mutations of TGF-β signaling are observed
in over 80% of proximal colon carcinomas [12]. To explore major affected pathways, we ana-
lyzed for alterations in multiple pathways implicated in colon cancer (Fig 1C). Two adenomas,
1 sessile serrated adenoma MDA51ad-SSA and 1 tubular adenoma MDA50ad-TA exhibit mul-
tiple mutations in WNT and RAS/PI3K pathways, and hypermutation-associated genes, such
as mismatch-repair gene MLH1 and PMS2 [12, 19], and DNA polymerase epsilon POLE,
which has frequent mutations in hypermutated CRC tumors [12]. Surprisingly, two high muta-
tion adenoma samples (MDA50ad-N/T) and MDA51ad-N/T) show frequent mutations in
TGF-β and CEA-related genes, suggesting that these two adenomas could be on the brink of
overt CRC (Fig 1C). The mutations in CEA-related genes in MDA50ad-N/T are in the CEA
(gene CEACAM5) at position 84 (an Alanine-to-Threonine mutation transversion) and in
CEACAM6 at residue 307 (a Glycine-to-Cysteine transversion). The adenoma genomic pro-
files revealed distinct mutational signatures regardless of adenoma histopathology, location, or
adenoma size (Fig 1C and S1 Dataset).
Next, we looked for variants in all genes in the sequencing data. Among all the adenoma
samples we observed that six genes had a high mutation frequency. These genes include APLF
(Aprataxin and PNKP like Factor), KLK11 (Kallikrein-Related Peptidase 11), LAMA5 (Lami-
nin, Alpha 5), MUC2 (Mucin 2), SIX5 (SIX Homeobox 5), and WDR90 (WD Repeat Domain
90) which are present in 36% of samples (Fig 1D, upper panels). Surprisingly, these genes are
not frequently mutated in the hypermutated (0–8.6%) and non-hypermutated (0–1.1%) TCGA
CRC carcinoma cohort [12] (Fig 1D, lower panel). Compared with proximal adenomas, the
mutation frequencies of these genes are more significant in the distal adenomas, suggesting
that they may play a barrier function in distal adenomas. Comparison of the mutational spec-
trums in our cohort to a set of 20 commonly mutated genes characterized in the TCGA CRC
carcinoma cohort indicates that APC mutations are found in both tubular adenoma
(MDA49ad-TA) and sessile serrated adenoma (MDA51ad-SSA) adenomas (Fig 1C). A KRAS
mutation is observed in tubular adenoma (MDA1ad-TA) (S3A Fig). Several well-established
cancer mutated genes such as TP53, PIK3CA, SMAD4, BRAF, and NRAS are not observed in
our cohort. This may be either due to later stage mutations or the small sample size (S3A Fig
and S1 Dataset) [12].
Aberrant TGF-β/CEA Profiles in Colon Adenomas
PLOSONE | DOI:10.1371/journal.pone.0153933 April 21, 2016 3 / 16
Fig 1. Frequent mutations are observed in colon adenomas. (A) Mutation frequency detected by whole-genome (WGS) sequencing of colon adenoma
tissues. The dot represents the number of mutations per Mb in one adenoma sample. The red and orange diamonds represent the median mutation per Mb
as observed in the colorectal cancer samples from the TCGA database. (B) Transitional single nucleotide substitutions of C:G > T:A predominate in the
adenomamutational spectrum. (C) Mutation profile of 4 pairs of matched colon adenoma samples and normal mucosa. Each colored dot indicates a mutation
in the sample. *: adenomas with high mutation rates. TA: Tubular adenoma; TVA: Tubulovillous adenoma; SSA: Sessile serrated adenoma. Location d:
distal; p: proximal. (D) Six most commonly mutated genes observed in 11 colon adenoma tissues (upper panels). These commonly mutated genes in
adenoma samples are not frequently mutated in the hypermutated (n = 35, 0–8.6%) and non-hypermutated (n = 189, 0–1.1%) TCGA CRC carcinoma cohort
(total n = 224, lower panel).
doi:10.1371/journal.pone.0153933.g001
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To identify gene expression profiles in the adenomas, unsupervised hierarchical clustering
was carried out for the 7 adenoma samples (cut off, p<0.05) (Fig 2A). The clustering heat map
reveals a unique cluster of gene signatures in two of the highly mutated adenoma samples,
MDA34ad-TVA and MDA27ad-TA. Together, the samples had a total of 910 up-regulated
genes and 549 down-regulated genes (cut off, log2 fold change ± 1.5) (Fig 2B). To validate the
identified gene expression in CRC, a transcriptome sequencing data set for CRC of 262 samples
was downloaded from the CRC TCGA cohort and 224 of these samples were analyzed (S3B
Fig). We found that the majority of genes with altered expression profiles in MDA34ad-TVA
and MDA27ad-TA adenomas correlate with the profiles in CRC. Of the genes with increased
expression profiles fromMDA34ad-TVA and MDA27ad-TA, 98% (197/221) were also up-reg-
ulated in TCGA CRC; of those genes with decreased expression profiles, 83% (247/295) were
down-regulated in CRC (cut-off, log2fold change ± 1.5) (Fig 2B).
Among the unique gene expression signatures identified in both the two adenoma samples
and the CRC TCGA cohort, we observe 26 commonly activated genes and 51 commonly inacti-
vated genes (Fig 2B). The commonly increased genes in these two adenoma samples include
KLK11 (Fig 2C), which is also mutated in 4 of 11 adenoma samples. The genes CDH3, ECM1,
IGFBP2, and MET, which are associated with cell adhesion, the extracellular matrix, and can-
cer cell invasion/metastasis, are also observed frequently increased in these two adenoma sam-
ples (Fig 2C). The commonly repressed genes in these two adenoma samples include BCL2L11,
TP53INP2, HIST1H1C, TRPM6, MIR22HG, and MIR5047 (Fig 2C). In MDA27ad-TA, there
is decreased expression of the TGF-β pathway members, including BMP2 and SMAD3, as well
as TGF-β/SMAD3’s targets such as DES and CDKN2B (Fig 2D). In MDA34ad-TVA, there is a
similar decrease in the expression of TGF-β/SMAD3’s targets, such as CDKN1A, FOS, and
NEDD4L (Fig 2E). Surprisingly, we also find that some stem cell-associated genes such as
ALDH1L1 and CXCL1/3 are increased in the MDA34ad-TVA adenoma sample, suggesting a
stem cell phenotype (Fig 2E) [8, 20]. Unsupervised hierarchical clustering of CRC TCGA data
sets was also performed. The clustering heat map of CRC carcinoma samples shows that 26
commonly activated genes observed in adenomas are markedly increased (in Cluster 1 and 2),
whereas 3 commonly inactivated genes are dramatically decreased (in Cluster 3) (S3B Fig).
CEA (gene CEACAM5), a 180kDa GPI-linked membrane glycoprotein, belongs to a sub-
group of the immunoglobulin supergene family CEACAMs [21, 22]. Studies have shown that
CEA and CEACAM6 levels are elevated in colon cancer patients [23–25]. We observed
markedly increased CEA (CEACAM5) levels in the highly mutated adenoma samples
MDA34ad-TVA and MDA27ad-TA, compared with matched normal mucosa samples (Fig
3A). Additionally, analysis of an OncomineTM dataset demonstrates high CEA mRNA levels in
colon and rectal adenomas (Fig 3B). Despite extensive investigation and identification of other
pro-tumorigenic CEACAMs, the functional role of the CEACAMs in CRC progression is
poorly understood. We have previously shown that CEA associates with TGF-β receptor 1
(TGFBR1) and inhibits TGF-β signaling which increases CRC liver metastasis [24]. Because we
also observed frequent mutations in TGF-β signaling pathways in adenomas, we sought to
determine a potential association between the expression levels of CEA and members of the
TGF-β signaling pathway including TGFBR1, TGFBR2 and Smads adaptor β2SP in 26 early
adenomas and 10 normal colon tissues (Fig 3C). We observed a marked increase in CEA
expression (nearly 5-fold) in 23% of adenoma samples with a concomitant loss of TGF-β sig-
naling confirmed by a further analysis of 40 samples.
We next explored how increased CEA levels could disrupt the TGF-β pathway by examining
the physical interactions between CEA and TGFBR1. For this, we generated a series of CEA
and TGFBR1 deletion mutants (Fig 4A, left panel). Immunoprecipitation assays demonstrate
that the B3 domain of CEA directly interacts with TGFBR1 (Fig 4A, right panel), and that the
Aberrant TGF-β/CEA Profiles in Colon Adenomas
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Fig 2. Unsupervised hierarchical clustered transcriptomic analysis reveals distinct gene expression signatures. (A) The clustering heat map reveals
a unique cluster of gene signatures in two of the highly mutated adenoma samples, MDA34ad-TVA and MDA27ad-TA. The heat map was obtained using the
7 adenoma samples with the Ward hierarchical clustering algorithm and Euclidean distance metrics. The samples are classified as intermediate, low, and
high based on the mutation rates observed. A unique cluster of genes was identified in two of the highly mutated adenoma samples, MDA34ad-TVA and
MDA27ad-TA. (B) Venn diagram representing the CRC TCGA data set and the 2 highly mutated adenoma samples which show the unique cluster of genes.
The red Venn diagram represents the genes (n = 910) that are up-regulated among the 2 highly mutated adenoma samples and the TCGA data set while the
green indicates the genes (n = 549) that are down-regulated as observed among the 2 highly mutated adenoma samples and the TCGA data set (cut-off,
log2fold change ± 1.5). (C) The commonly altered genes which are observed in two adenoma samples, MDA27ad-TA and MDA34ad-TVA. The
representative gene expressions are shown. (D) Representative altered gene expressions are shown in adenoma sample MDA27ad-TA. (E) Representative
altered gene expressions are shown in adenoma sample MDA34ad-TVA.
doi:10.1371/journal.pone.0153933.g002
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Fig 3. Enhanced expression of CEA correlates with loss of TGF-β signaling in early colon adenomas. (A) Marked increases in CEAmRNA expression
levels in the highly mutated adenoma samples, MDA27ad-TA and MDA34ad-TVA. CEAmRNA expression levels were detected in 4 adenomas (MDA27ad-
TA, MDA34ad-TVA, MDA2ad-TVA, and MDA3ad-SSA) and 4 matched normal mucosa samples (MDA27nor, MDA34nor, MDA2nor, and MDA3nor) by
Q-RT-PCR. Results are the average of three independent experiments and are presented as mean ± SD. *p < 0.01, versus normal tissues, Student’s t-test.
(B) Analysis of an Oncomine™ dataset demonstrates high CEAmRNA levels in colon and rectal adenomas compared to that in corresponding normal
colorectal tissue. CEA and CEACAM6mRNA expression is inversely associated with TGF-β target gene levels in normal and adenoma colorectal tissues.
Transcriptomic profiles of 32 colorectal adenoma tumors and their 32 corresponding normal colorectal tissue were downloaded from Gene Expression
Omnibus database (data set GSE8671). These gene expression profiles were then analyzed using Oncomine analysis tools (www.oncomine.org). Data are
displayed as a heat map using an Oncomine™ graphic platform and as a dot plot using a GraphPad Prism v5.0 program. *: p < 0.05, Student’s t-test. (C)
Aberrant TGF-β/CEA Profiles in Colon Adenomas
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N-terminus domain of TGFBR1 (amino acids 1–104 of the extracellular domain) is required
for interacting with CEA (Fig 4B). In vitro binding assays reveal that the CEA B3 domain inter-
acts directly with TGFBR1 (Fig 4C).
Further analysis demonstrates that the B3 domain of CEA inhibits TGF-β-stimulated phos-
phorylation of Smad3 (Fig 5A). Over expression of CEA in HCT116 cells significantly alters
TGF-β/Smad3 transcriptional targets as evidenced from the Q-RT-PCR assays (Fig 5B). The
luciferase reporter assays demonstrate that the B3 domain of CEA inhibits TGF-β-induced
Smad3 transcriptional activates in both HCT116 and SW837 cells (Fig 5C). Knockdown of
CEA in colon cancer DLD1 cells increased TGFBR1 protein stability, suggesting that CEA may
regulate TGFBR1 levels post-transcriptionally (Fig 5D). Also, we examined the effect of CEA
knockdown on the proliferation and migration in DLD1-shCtrl and DLD1-shCEA CEA
knockdown cells with and without TGF-β treatment. Our data indicate that knockdown CEA
in CRC cells significantly suppresses cell growth. TGF-β treatment of CEA knockdown cells
has more marked inhibitory effect on cell proliferation (Fig 5E). Strikingly, TGF-β significantly
suppresses cell migration in DLD1 CEA knockdown cells, while increasing cell migration in
control DLD1-shCtrl cells (Fig 5F). The data suggest that TGF-β plays a tumor suppressor
function in the context of loss of function of CEA in these CRC cells. Taken together, these
results support that CEA disrupts the TGF-β pathway by interfering with TGFBR1 stability,
which in turn blocks the Smad3 phosphorylation cascade and its downstream transcriptional
targets (Fig 5G).
Discussion
Although there are 3 effective clinical chemo-preventive agents (i.e., Vitamin D/calcium, estro-
gen-containing hormone replacement therapies, aspirin/NSAIDs/COXIBs) [26], these are used
less frequently than expected because of their limited efficacy and/or high toxicity. However,
these agents provide proof of principle for chemoprevention in CRC and suggest important
concepts on which to build future developmental studies. The current cancer risk prediction
models mostly rely on environmental risk factors and so have modest discriminatory accuracy.
Our approach towards improved risk prediction incorporates genetic information and bio-
marker-driven models used in conjunction with animal models. For other cancers, intermedi-
ate phenotypic biomarkers have yielded improved risk prediction. For instance, mutagen
sensitivity in lymphocytes has been used as an indirect measure of latent genetic instability.
Yet, there still have been no concerted efforts thus far to identify intermediate phenotypic bio-
markers in CRC risk prediction. The largest gap of knowledge is the lack of integrative risk
models for any stage of the CRC continuum. We begin addressing these issues through our
analysis of normal/neoplastic tissues from individuals with pre-invasive colonic neoplasms
that are suspected of developing a premalignant genome analysis. Our studies further support
an important functional role for CEA and TGF-β signaling in early benign adenomas (polyps)
that give rise to CRC.
Surveillance colonoscopy has been advised every 3–5 years for individuals with a history of
adenomas; individuals with an adenoma-free history are recommended to do so every 10 years.
This creates a large burden on surveillance colonoscopy, which accounts for 25% of the total
colonoscopies performed annually in the United States [5]. Considering this, there is an urgent
Adenoma samples analysis of CEA, TGFBR1, TGFBR2, and β2SP reveals a negative correlation between CEA and TGF-β genes in colon adenomas.
Sections from human clinical samples of normal (n = 10) and adenoma colon tissue (n = 26) were prepared and processed for immunohistochemical
analysis, with further confirmation using 40 adenomas. Magnification × 20; insets magnification × 60. Scale bars, 10 mm. Quantification of the
immunohistochemical staining is shown. Mean ± SD is shown *: p < 0.01, Student’s t-test.
doi:10.1371/journal.pone.0153933.g003
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Fig 4. CEA interacts with the TGF-β pathway. (A) The CEA B3 domain is required for the interaction of CEA with TGFBR1. HCT116 cells were co-
transfected with the generated mutants. Cell lysates were immunoprecipitated with the CEA antibody and were immunoblotted with the indicated antibodies.
(B) CEA interacts with the extracellular domain of TGFBR1 (amino acid 1–104). The generated TGFBR1mutant plasmids were co-transfected into the cell
lines and immunoprecipitation was carried out with CEA antibodies, followed by immunoblotting. (C) The CEA B3 domain interacts directly with TGFBR1.
The CEA B3 domain GST fusion protein was produced bacterially. HA-TGFBR1-FL or HA-TGFBR1-1-104 deletion plasmids were transfected in 293T cells.
Purified TGFBR1-FL (full length) or HA-TGFBR1- del-1-104 was incubated with GST-empty or GST-CEA-B3 proteins. The binding of TGFBR1 to CEA-B3
domain was detected by immunoblotting using anti-HA antibody. * designates non-specific bands. Purified GST fashion proteins were detected by
Coomassie blue staining. Glutathione Resin GST Fusion Protein Purification Kit (GenScript, Cat. L00206) was used for purification of GST-CEA-B3 domain
fusion protein.
doi:10.1371/journal.pone.0153933.g004
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Fig 5. CEA interacts with and disrupts the TGF-β pathway. (A) Overexpression of CEA B3 domain prevents TGF-β-induced Smad3 phosphorylation.
HCT116 cells were co-transfected with CEA wild type (FL) or various CEA deletion mutants. The cells were stimulated with TGF-β1 for 2 hours. The cell
lysates were immunoblotted with the indicated antibodies. (B) CEA transcriptionally regulates TGF-β pathways. HCT116 cells were transfected with CEA.
The mRNA levels of TGF-β targets were detected by Q-RT-PCR. The result shown is representative of three independent experiments. (C) Overexpression
of CEA B3 domain inhibits Smad3 transcriptional activity. HCT116 or SW837 cells were co-transfected with Smad3 luciferase reporter plasmids, CEA (FL,
N-A3, and B3), and Renilla luciferase reporter plasmids. The cells were stimulated with TGF-β1 for 2 hours. Cell lysates were collected and analyzed
according to the manufacturer’s protocol. Results are the average of three independent experiments and are presented as mean ± SD. *p < 0.01, compared
with Flag-Smad3/TGF-β1 treatment in Vector-Ctrl cells. Student’s t-test. NS: not significant. (D) CEA knockdown increases TGFBR1 protein stability. DLD1
cells were knocked down with control or shCEA. Cells were treated with 100ug/ml cycloheximide (CHX) for the indicated times. The density of TGFBR1 or
Aberrant TGF-β/CEA Profiles in Colon Adenomas
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need to develop new techniques which will facilitate early detection of the disease. Convention-
ally, high-risk adenomas are defined clinically as those that are larger than 1 cm. These adeno-
mas are considered to give rise to overt carcinomas and are an important criterion in
colonoscopy and screening studies [3, 4, 6, 7]. We attempted to identify high-risk genetic pro-
files of adenomas which could develop to rapid-onset CRC. We describe the genetic analysis of
four sets of colonic adenoma tissue samples paired with their normal counterparts using
whole-genome sequencing analysis. We extend this to transcriptomic analysis of seven further
pairs of adenomas. We propose that our observations of several types of precancerous muta-
tions and transcriptomic profiles in 4 out of the 11 adenomas may be used clinically to predict
higher risk of transformation to CRC. In one of the two samples, surprisingly high mutational
profiles of multiple genes, including CEA and CEACAM6, is demonstrated. Transcriptomic
analyses and immunohistochemical analysis of adenoma tissue samples further demonstrate
enhanced CEA expression and concomitant loss of TGF-β signaling components in 23% ade-
noma samples.
TGF-β is a key regulator of multiple biological processes, including cell proliferation, differ-
entiation, migration, apoptosis [27, 28], and tumor suppression in early stages of cancer. Yet,
in later stages it is pro-metastatic [29]. Current data support TGF-β signaling as a suppressor
of early colorectal cancers [30, 31]. In later stages of the disease, metastatic CRCs escape the
tumor-suppressor effects of TGF-β signaling by becoming both resistant to TGF-β-induced
growth inhibition and harnessing the pro-tumorigenic properties of TGF-β [24]. Inactivating
mutations in TGFBR2 occur in 87% of human colorectal carcinomas with microsatellite insta-
bility [32].
Recent studies have demonstrated that CEACAM functions are pleiotropic, including inter-
cellular adhesion [22, 33], modulation of cell homeostasis [34], T-cell proliferation [35, 36],
neovascularization. Also, CEACAM functions as a receptor for host-specific viruses and bacte-
ria that harness the CEACAMs for successful host colonization [37]. CEA and CEACAM6 are
considered to be pro-tumorigenic in colon cancer. CEA has been utilized as a marker for recur-
rent disease in CRC, and also in thyroid and pancreatic cancer [38, 39]. While CEA vaccines
have been utilized in advanced CRC, they have yet to be studied in the prevention arena; thus,
our study warrants a large cohort analysis of vaccination and prevention measures in high-risk
populations of patients with colon adenomas that have aberrant TGF-β signaling concurrent
with overexpression of CEA. Collectively, our analysis may provide an important approach to
prevent CRC and identify high-risk patients with surprisingly high mutational profiles or who
expresses high CEA earlier than previously thought. Further work may lead to a new paradigm
in the cost-effective prevention of CRC.
Materials and Methods
Patients and samples
We performed whole-genome sequencing on 4 pairs of adenoma samples and whole-transcrip-
tome RNA sequencing on 7 matched colon adenoma samples and normal mucosa obtained
from the University of Texas, MD Anderson Cancer Center (GSE72820).
TGFBR2 and the integrated optical density were measured. The turnover of TGFBR1 or TGFBR2 is indicated graphically. (E) Knock down CEA and/or TGF-
β treatment suppresses CRC cell growth. Cell proliferation was assessed by colorimetric MTS assays. Results are the average of three independent
experiments and are presented as mean ± SD. *p < 0.01, Student’s t-test. (F) TGF-β significantly suppresses cell migration in DLD1 CEA knockdown cells,
while increasing cell migration in control DLD1-shCtrl cells. Transwell migration assays of DLD1-shCtrl or DLD1-shCEA cells were performed. Cells were
treated with TGF-β1 (200pM) for 24 hours. Results are the average of three independent experiments and are presented as mean ± SD. *p < 0.05,
**p < 0.01, Student’s t-test. (G) Proposed model of the role of CEA in the regulation of TGF-β pathway.
doi:10.1371/journal.pone.0153933.g005
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We analyzed the transcriptome (n = 262) and screened for mutations (n = 224) in CRC
patients from The Cancer Genome Atlas (TCGA) downloaded on November 2014. In addition,
transcriptomic profiles of 32 colorectal adenomas tumors and their 32 corresponding normal
colorectal tissues were downloaded from Gene Expression Omnibus database (GSE8671).
These gene expression profiles were then analyzed using Oncomine™ analysis tools (www.
oncomine.org). Data were displayed as a heat map using an Oncomine™ graphic platform and
as a dot plot using a GraphPad Prism v5.0 program. The study was approved by the Office of
Human Subjects Research of the National Institutes of Health and MD Anderson Cancer Cen-
ter, and all samples were de-identified.
Cell culture, transfection, and shRNA-mediated silencing
Human colon epithelial cell line DLD-1 (ATCC, CCL-221), HCT 116 (ATCC1 CCL-247™)
and SW837 (ATCC1 CCL-235™) were cultured in DME/F12 medium, and (Sigma Aldrich,
D5671) supplemented with 10% fetal bovine serum (Sigma Aldrich, F2442). Transfection of
CEA plasmid constructs was carried out using Lipofectamine 2000 (Invitrogen). Lentiviral par-
ticles containing CEA (sc-36551) or control shRNA lentiviral particles (sc-108080) were pur-
chased from Santa Cruz Biotechnology and were used to infect DLD1 cells.
Cell growth and viability assays
Cell proliferation was assessed by a colorimetric MTS assay according to the manufacturer's
instructions (Cell Titer 96 Aqueous One Solution Cell Proliferation Assay; Promega, Madison,
WI, USA, Ca# G3580). A total of 5 × 103 cells were seed in 96 well plates at day 0. Beginning
the next day, cells were treated with TGF-β1 (200pM) each day (day 1 to day 6). For measuring
cell numbers, the cells were incubated for 3 h with MTS solution. Subsequently, the absorbance
was measured at 490 nm on an ELISA reader (BioRad Model 550).
Immunohistochemical analysis
Sections from human clinical samples of normal (n = 10) and adenoma colon tissue (n = 26)
were prepared and processed for immunohistochemical analysis using antibodies against CEA,
TGFBR1, TGFBR2, and β2SP. Staining intensities were measured between the normal and ade-
noma samples in at least five different fields. Protein expression was objectively and quantita-
tively measured using an ACIS III automatic cellular imaging system (DAKO) equipped with
automatic microscopy and advanced computerized image analysis.
Construction of the plasmids and stable cell lines
cDNA sequence of TGFBR1 was amplified by gene-specific primer and inserted into
pCMV-HA mammalian expression vectors (pCMV-HA) (Clonetech). To construct
pCMV-HA-TGFBR1 (del-1-104), N-A3, N-B2 and B3 domain of CEA, cDNA sequence of
each gene was amplified by site-specific polymerase chain reaction, and then subsequently sub-
cloned into the same mammalian expression vector. To generate a stable shCEA cell line,
HEK293T cells were transfected with the indicated lentiviral plasmid DNAs to make lentiviral
particles through the viral packaging process. Virus-containing supernatants were collected
and filtered, then DLD1 cells were infected with lentiviral particles, either shLuciferase or
shCEA with 8 μg/ml of polybrene. After infection, cells were selected with 2–4 μg/mL of puro-
mycin for 2 weeks.
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Immunoprecipitation
To analyze the interaction of CEA with TGFBR1, HCT116 cells were co-transfected with FL,
N-B2 and N-A3 CEA with either HA-TGFBR1-FL or HA-TGFBR1-del 1–104 plasmid DNA.
Cells were incubated for 48hrs, and were lysed with lysis buffer [20mM Tris (Fisher), 100mM
NaCl (Fisher), 0.5% Nonidet P-40 (USB Corp.), 0.5% Triton X-100 (Sigma), 1mM EDTA
(Fisher)]. Fresh protease/phosphatase inhibitors [5 mM NaV, 1 mM NaF, 1 μMDTT, 0.1 mg/
mL Pepstatin A, 1 mM PMSF, and 1,000× Complete Mixture Protease Inhibitor (Roche)] were
added into the lysis buffer. For IP, lysed cells were incubated with CEA antibody (Thermo MS-
613-P0) for 2 hours at 4°C and then incubated with protein G plus agarose beads (Amersham)
for 2 hours at 4°C. Beads were washed with TBST and were subjected to immunoblotting.
GST pull-down and in vitro binding assays
BL21 cells were transformed with pGEX-2TK or pGEX-2TK-CEA-B3 and incubated with 0.2
mM IPTG for 4 hours. The GST fusion proteins were purified from bacterial lysates with
GSH-Sepharose 4B beads according to the manufacturer’s instruction (GenScript, Cat.
L00206). 293T cells were transfected with HA-TGFBR1-FL or HA-TGFBR1-del-1-140 and HA
fusion proteins were immunoprecipitated and purified from cell lysates using HA-tagged pro-
tein purification kit (MBL, 3320A). For the GST pull-down assay, cell lysates were prepared by
sonication and spun at 15,000 rpm for 15 min. The supernatants were incubated with GST
sepharose beads for 3 h at 4°C. For the in vitro binding assay, purified HA-TGFBR1-FL or
HA-TGFBR1-del-1-140 was incubated with a GST or GST- CEA-B3 fusion protein that conju-
gated to Sepharose beads in 500 μl of reaction buffer (50 mM Tris-HCl, pH 7.5, 150 mMNaCl,
5 mM NaF, 1% NP40, and protease inhibitor mixture) for 12 h at 4°C. After centrifugation, the
proteins bound to Sepharose beads were washed with cold PBS, mixed with SDS sample buffer.
The binding of TGFBR1 to CEA-B3 domain was detected using anti-HA antibody.
In vitro migration and invasion assay
For transwell migration assays, 1 × 105 cells were plated in the top chamber with the non-
coated membrane (24-well insert; Cat. 3422, Corning). The cells were plated in medium with-
out serum or growth factors, and medium supplemented with serum was used as a chemoat-
tractant in the lower chamber. Cells were incubated for 24 hours with or without TGF-β1
(200pM) and cells that did not migrate through the pores were removed by a cotton swab.
Cells on the lower surface of the membrane were stained with the Diff-Quick Staining Set
(Dade) and counted.
Western blotting and antibodies
Cells were lysed with lysis buffer and were standardized using a BCA protein assay (Pierce™ BCA
Protein Assay Kit 23225). Equal amounts of proteins were fractionated on SDS–PAGE and blot-
ted to nitrocellulose membrane. Membranes were incubated with CEA (ThermoMS-613-P0),
TGFBR1 (Santa Cruz Sc-398), TGFBR2 (ab17650), Phospho-Smad3 (Ser423/425) (Cell Signaling
#9520), Smad3 (Cell Signaling #9523), and tubulin (Cell Signaling #2144) antibodies. Secondary
antibodies conjugated with horseradish peroxidase (Chemicon) and Enhanced chemilumines-
cence (ECL) kit (Perkin-Elmer Life Sciences) were used to develop the immunoblots.
Luciferase assays
To analyze Smad3 transcriptional activity, HCT116 cells or SW378 cells were seeded at a den-
sity of 1x104 cell/well in 24-well culture dishes. Cells were co-transfected with Smad3 luciferase
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reporter plasmid, CEA (FL, N-A3 and B3) and Renilla luciferase reporter plasmids. After trans-
fection, cells were incubated in a serum-free media for 24h and were treated with either TGF-
β1 or vehicle and then incubated for a further 2 hours. At harvest, cells were collected using
passive lysis buffer (Promega) and analyzed according to the manufacturer’s protocol for the
Dual Luciferase Reporter Assay kit (Promega).
Statistical analyses
Pairwise comparisons were performed using Student’s t-test  P< 0.01. Graphs represent
mean ± standard deviation unless otherwise noted.
Supporting Information
S1 Dataset. Somatic mutations in adenoma samples.
(XLSX)
S1 Fig. Histologic specimen of human colorectal adenoma tissue stained with hematoxylin
and eosin. Eleven pairs of matched colon adenoma samples and normal mucosa were obtained
from the University of Texas, MD Anderson Cancer Center. Four pairs were for whole-genome
sequencing and a further 7 pairs were for whole-transcriptome RNA sequencing analyses.
(TIF)
S2 Fig. Frequent mutations are observed in colon adenomas by WTS. (A) Mutation fre-
quency detected by whole-transcriptome (WTS) sequencing of colon adenoma tissues. The dot
represents the number of mutations per Mb in one adenoma sample. The red and orange dots
represent the median mutation per Mb as observed in the colorectal cancer samples from the
TCGA database. (B) Transitional single nucleotide substitutions of C:G> T:A predominate in
the adenoma mutational spectrum.
(TIF)
S3 Fig. Gene profiles of the adenomas. (A) The top 20 common gene mutations observed in
the CRC TCGA data set were examined in 11 colon adenoma tissues (left panel). The overall
percentage of mutations observed in the CRC TCGA data set is presented with divided per-
centages calculated for the proximal and distal (right panel). TA: Tubular adenoma; TVA:
Tubulovillous adenoma; SSA: Sessile serrated adenoma. Location d: distal; p: proximal. (B) A
heat map of the CRC TCGA data set with 26 commonly activated and 3 most commonly inac-
tivated genes which were observed in both the 2 adenoma samples MDA34ad-TVA and
MDA27ad-TA, and the CRC TCGA samples. Three clusters are shown, two from the up-regu-
lated clusters and one from the down-regulated cluster. The significant genes from the clusters
are represented (cut off, p<0.05).
(TIF)
S1 Methods.
(DOCX)
S1 Table. Mutation frequency of adenoma samples.
(DOCX)
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